Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech

Up to $1.4 billion is at stake in a licensing agreement between Novo Nordisk and Danish biotech Orbis Medicines, signed on September 17, 2026. The pact deepens Novo's strategic investment in oral peptide drugs, focusing on the therapeutic capabilities of macrocycles. Through this alliance, Novo Nordisk aims to engineer oral treatments designed to address widespread cardiometabolic diseases, expanding beyond conventional injectable therapies.

The transaction directly affects Orbis Medicines, a Danish biotechnology firm that previously drew backing from rival drugmaker Eli Lilly, as noted by Endpoints News. Novo Nordisk gains licensed access to Orbis's macrocycle platform, reinforcing its proprietary pipeline against competing pharmaceutical developers. For Orbis, the agreement pairs its specialized oral drug design capabilities with the scale and clinical resources of an established metabolic medicine manufacturer.

Moving forward, the partners will focus on the research and development of oral therapeutic candidates targeted at cardiometabolic diseases. Progress will depend on advancing these licensed macrocycles through initial validation and regulatory development phases. Specific candidate milestones and clinical trial launch timelines have not been publicly detailed by either company.